{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T12:15:03Z","timestamp":1778588103827,"version":"3.51.4"},"reference-count":84,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T00:00:00Z","timestamp":1779408000000},"content-version":"am","delay-in-days":325,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100015919","name":"A Glimmer of Hope","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100015919","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["T32 CA 009599"],"award-info":[{"award-number":["T32 CA 009599"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA016672"],"award-info":[{"award-number":["P30 CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["Multi-PI R01"],"award-info":[{"award-number":["Multi-PI R01"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005301","name":"American College of Surgeons","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005301","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000090","name":"Congressionally Directed Medical Research Programs","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000090","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","surgonc.theclinics.com","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Surgical Oncology Clinics of North America"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.soc.2025.01.003","type":"journal-article","created":{"date-parts":[[2025,2,27]],"date-time":"2025-02-27T15:27:51Z","timestamp":1740670071000},"page":"359-374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Systemic Therapy for Melanoma"],"prefix":"10.1016","volume":"34","author":[{"given":"Ashlee N.","family":"Seldomridge","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roi","family":"Weiser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley M.","family":"Holder","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6257","key":"10.1016\/j.soc.2025.01.003_bib1","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1126\/science.aad0095","article-title":"Genomic correlates of response to CTLA-4 blockade in metastatic melanoma","volume":"350","author":"Van Allen","year":"2015","journal-title":"Science"},{"issue":"23","key":"10.1016\/j.soc.2025.01.003_bib2","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1406498","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"371","author":"Snyder","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib3","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","article-title":"Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma","volume":"165","author":"Hugo","year":"2016","journal-title":"Cell"},{"issue":"10304","key":"10.1016\/j.soc.2025.01.003_bib4","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/S0140-6736(21)01206-X","article-title":"Immune checkpoint inhibitors in melanoma","volume":"398","author":"Carlino","year":"2021","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.soc.2025.01.003_bib5","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1245\/s10434-019-08183-0","article-title":"Toxicity of immune checkpoint inhibitors: considerations for the surgeon","volume":"27","author":"Helmink","year":"2020","journal-title":"Ann Surg Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.01.003_bib6","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/j.trecan.2023.04.002","article-title":"Immune mechanisms of toxicity from checkpoint inhibitors","volume":"9","author":"Wang","year":"2023","journal-title":"Trends Cancer"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib7","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/COC.0000000000000239","article-title":"CTLA-4 and PD-1 pathways: similarities, differences, and implications of their inhibition","volume":"39","author":"Buchbinder","year":"2016","journal-title":"Am J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib8","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1186\/s13046-019-1259-z","article-title":"Combination of CTLA-4 and PD-1 blockers for treatment of cancer","volume":"38","author":"Rotte","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"issue":"16","key":"10.1016\/j.soc.2025.01.003_bib9","doi-asserted-by":"crossref","first-page":"4373","DOI":"10.1016\/j.cell.2024.06.036","article-title":"Blockade of LAG-3 and PD-1 leads to co-expression of cytotoxic and exhaustion gene modules in CD8(+) T cells to promote antitumor immunity","volume":"187","author":"Cillo","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.soc.2025.01.003_bib10","unstructured":"Referenced with permission from the NCCN clinical practice guidelines in Oncology (NCCN Guidelines\u00ae) for guideline name V.2.2024. \u00aeNational Comprehensive cancer Network, Inc. All rights reserved. Accessed December 5, 2024, 2024. to view the most recent and complete version of the guideline, go online to NCCN.org."},{"issue":"5","key":"10.1016\/j.soc.2025.01.003_bib11","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1016\/j.cels.2020.10.002","article-title":"Receptor-driven ERK pulses reconfigure MAPK signaling and enable persistence of drug-adapted BRAF-mutant melanoma cells","volume":"11","author":"Gerosa","year":"2020","journal-title":"Cell Syst"},{"issue":"22","key":"10.1016\/j.soc.2025.01.003_bib12","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1038\/sj.onc.1210421","article-title":"MAP kinase signalling pathways in cancer","volume":"26","author":"Dhillon","year":"2007","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.soc.2025.01.003_bib13","doi-asserted-by":"crossref","first-page":"1877","DOI":"10.1056\/NEJMoa1406037","article-title":"Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma","volume":"371","author":"Long","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.soc.2025.01.003_bib14","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/S1470-2045(16)30122-X","article-title":"Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial","volume":"17","author":"Ascierto","year":"2016","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.soc.2025.01.003_bib15","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1016\/S1470-2045(18)30497-2","article-title":"Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, phase 3 trial","volume":"19","author":"Dummer","year":"2018","journal-title":"Lancet Oncol"},{"issue":"9992","key":"10.1016\/j.soc.2025.01.003_bib16","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/S0140-6736(15)60898-4","article-title":"Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial","volume":"386","author":"Long","year":"2015","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.soc.2025.01.003_bib17","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.soc.2025.01.003_bib19","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1007\/s00262-020-02839-7","article-title":"T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model","volume":"70","author":"Stahlie","year":"2021","journal-title":"Cancer Immunol Immunother"},{"issue":"7","key":"10.1016\/j.soc.2025.01.003_bib20","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1056\/NEJMoa1904059","article-title":"Five-year outcomes with dabrafenib plus trametinib in metastatic melanoma","volume":"381","author":"Robert","year":"2019","journal-title":"N Engl J Med"},{"issue":"10105","key":"10.1016\/j.soc.2025.01.003_bib21","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"issue":"16","key":"10.1016\/j.soc.2025.01.003_bib22","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"issue":"26","key":"10.1016\/j.soc.2025.01.003_bib23","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1104621","article-title":"Ipilimumab plus dacarbazine for previously untreated metastatic melanoma","volume":"364","author":"Robert","year":"2011","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.soc.2025.01.003_bib24","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S1470-2045(15)70076-8","article-title":"Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial","volume":"16","author":"Weber","year":"2015","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.01.003_bib25","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1200\/JCO.2016.71.8023","article-title":"Overall survival in patients with advanced melanoma who received nivolumab versus investigator\u2019s choice chemotherapy in CheckMate 037: a randomized, controlled, open-label phase III trial","volume":"36","author":"Larkin","year":"2018","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.soc.2025.01.003_bib26","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa1412082","article-title":"Nivolumab in previously untreated melanoma without BRAF mutation","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.soc.2025.01.003_bib27","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/S1470-2045(15)00083-2","article-title":"Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial","volume":"16","author":"Ribas","year":"2015","journal-title":"Lancet Oncol"},{"issue":"26","key":"10.1016\/j.soc.2025.01.003_bib28","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1056\/NEJMoa1503093","article-title":"Pembrolizumab versus ipilimumab in advanced melanoma","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2025.01.003_bib29","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1200\/JCO.21.02229","article-title":"Long-term outcomes with nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in patients with advanced melanoma","volume":"40","author":"Wolchok","year":"2022","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.01.003_bib30","doi-asserted-by":"crossref","first-page":"1558","DOI":"10.1016\/S1470-2045(16)30366-7","article-title":"Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial","volume":"17","author":"Hodi","year":"2016","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.01.003_bib31","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1200\/JCO.18.01998","article-title":"Evaluation of two dosing regimens for nivolumab in combination with ipilimumab in patients with advanced melanoma: results from the phase IIIb\/IV CheckMate 511 trial","volume":"37","author":"Lebb\u00e9","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.soc.2025.01.003_bib32","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.1200\/JCO.22.02072","article-title":"Nivolumab and relatlimab in patients with advanced melanoma that had progressed on anti-programmed death-1\/programmed death ligand 1 therapy: results from the phase I\/IIa RELATIVITY-020 trial","volume":"41","author":"Ascierto","year":"2023","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib33","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1056\/NEJMoa1412690","article-title":"Improved overall survival in melanoma with combined dabrafenib and trametinib","volume":"372","author":"Robert","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2025.01.003_bib35","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1200\/JCO.22.01763","article-title":"Combination dabrafenib and trametinib versus combination nivolumab and ipilimumab for patients with advanced BRAF-mutant melanoma: the DREAMseq trial-ECOG-ACRIN EA6134","volume":"41","author":"Atkins","year":"2023","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.01.003_bib36","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1200\/JCO.22.00343","article-title":"Randomized, double-blind, placebo-controlled, global phase III trial of talimogene laherparepvec combined with pembrolizumab for advanced melanoma","volume":"41","author":"Chesney","year":"2023","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.soc.2025.01.003_bib37","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1200\/JCO.2017.73.7379","article-title":"Randomized, open-label phase II study evaluating the efficacy and safety of talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone in patients with advanced, unresectable melanoma","volume":"36","author":"Chesney","year":"2018","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.soc.2025.01.003_bib38","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","article-title":"Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma","volume":"387","author":"Rohaan","year":"2022","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.soc.2025.01.003_bib39","doi-asserted-by":"crossref","first-page":"2656","DOI":"10.1200\/JCO.21.00612","article-title":"Lifileucel, a tumor-infiltrating lymphocyte therapy, in metastatic melanoma","volume":"39","author":"Sarnaik","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.01.003_bib40","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-005755","volume":"10","author":"Chesney","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"8","key":"10.1016\/j.soc.2025.01.003_bib42","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/oncolo\/oyae136","article-title":"Lifileucel: FDA-approved T-cell therapy for melanoma","volume":"29","author":"Kwong","year":"2024","journal-title":"Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.01.003_bib43","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S1470-2045(15)70122-1","article-title":"Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial","volume":"16","author":"Eggermont","year":"2015","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.soc.2025.01.003_bib44","doi-asserted-by":"crossref","first-page":"1824","DOI":"10.1056\/NEJMoa1709030","article-title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","volume":"377","author":"Weber","year":"2017","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.soc.2025.01.003_bib45","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1158\/2159-8290.CD-21-1141","article-title":"Adjuvant pembrolizumab versus IFN\u03b12b or ipilimumab in resected high-risk melanoma","volume":"12","author":"Grossmann","year":"2022","journal-title":"Cancer Discov"},{"issue":"3","key":"10.1016\/j.soc.2025.01.003_bib46","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1200\/JCO.22.00533","article-title":"Adjuvant therapy of nivolumab combined with ipilimumab versus nivolumab alone in patients with resected stage IIIB-D or stage IV melanoma (CheckMate 915)","volume":"41","author":"Weber","year":"2023","journal-title":"J Clin Oncol"},{"issue":"19","key":"10.1016\/j.soc.2025.01.003_bib47","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1056\/NEJMoa1708539","article-title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","volume":"377","author":"Long","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2025.01.003_bib48","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S1470-2045(18)30015-9","article-title":"Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial","volume":"19","author":"Amaria","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.01.003_bib49","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/S1470-2045(19)30331-6","article-title":"Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB\u2013C, <em>BRAF<\/em>V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial","volume":"20","author":"Long","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.soc.2025.01.003_bib50","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1038\/s41591-018-0198-0","article-title":"Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma","volume":"24","author":"Blank","year":"2018","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.soc.2025.01.003_bib51","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41591-018-0197-1","article-title":"Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma","volume":"24","author":"Amaria","year":"2018","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.soc.2025.01.003_bib52","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1038\/s41591-019-0357-y","article-title":"A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma","volume":"25","author":"Huang","year":"2019","journal-title":"Nat Med"},{"issue":"7","key":"10.1016\/j.soc.2025.01.003_bib53","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","article-title":"Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial","volume":"20","author":"Rozeman","year":"2019","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.soc.2025.01.003_bib54","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41591-020-01188-3","article-title":"Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)","volume":"27","author":"Menzies","year":"2021","journal-title":"Nat Med"},{"key":"10.1016\/j.soc.2025.01.003_bib55","doi-asserted-by":"crossref","first-page":"S1408","DOI":"10.1016\/j.annonc.2022.08.039","article-title":"LBA6 Neoadjvuant versus adjuvant pembrolizumab for resected stage III-IV melanoma (SWOG S1801)","volume":"33","author":"Patel","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.soc.2025.01.003_bib56","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2402604","article-title":"Neoadjuvant nivolumab and ipilimumab in resectable stage III melanoma","author":"Blank","year":"2024","journal-title":"N Engl J Med"},{"issue":"7934","key":"10.1016\/j.soc.2025.01.003_bib57","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41586-022-05368-8","article-title":"Neoadjuvant relatlimab and nivolumab in resectable melanoma","volume":"611","author":"Amaria","year":"2022","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.soc.2025.01.003_bib58","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s41591-022-01851-x","article-title":"Personalized response-directed surgery and adjuvant therapy after neoadjuvant ipilimumab and nivolumab in high-risk stage III melanoma: the PRADO trial","volume":"28","author":"Reijers","year":"2022","journal-title":"Nat Med"},{"issue":"10","key":"10.1016\/j.soc.2025.01.003_bib59","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1001\/jamaoncol.2023.2789","article-title":"Final 5-year follow-up results evaluating neoadjuvant talimogene laherparepvec plus surgery in advanced melanoma: a randomized clinical trial","volume":"9","author":"Dummer","year":"2023","journal-title":"JAMA Oncol"},{"issue":"13","key":"10.1016\/j.soc.2025.01.003_bib60","doi-asserted-by":"crossref","first-page":"4633","DOI":"10.1245\/s10434-019-07691-3","article-title":"Efficacy of talimogene laherparepvec (T-VEC) therapy in patients with in-transit melanoma metastasis decreases with increasing lesion size","volume":"26","author":"Masoud","year":"2019","journal-title":"Ann Surg Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib61","doi-asserted-by":"crossref","DOI":"10.4110\/in.2020.20.e9","article-title":"Clinical characteristics and treatment of immune-related adverse events of immune checkpoint inhibitors","volume":"20","author":"Choi","year":"2020","journal-title":"Immune Netw"},{"issue":"6","key":"10.1016\/j.soc.2025.01.003_bib62","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1016\/j.cell.2021.02.011","article-title":"Understanding and treating the inflammatory adverse events of cancer immunotherapy","volume":"184","author":"Dougan","year":"2021","journal-title":"Cell"},{"issue":"9","key":"10.1016\/j.soc.2025.01.003_bib63","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1002\/cncr.27969","article-title":"Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma","volume":"119","author":"Weber","year":"2013","journal-title":"Cancer"},{"issue":"36","key":"10.1016\/j.soc.2025.01.003_bib64","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1200\/JCO.21.01440","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: ASCO guideline update","volume":"39","author":"Schneider","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.soc.2025.01.003_bib65","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1002\/jcph.962","article-title":"Exposure-response analysis of nivolumab in patients with previously treated or untreated advanced melanoma","volume":"57","author":"Bajaj","year":"2017","journal-title":"J Clin Pharmacol"},{"issue":"14","key":"10.1016\/j.soc.2025.01.003_bib66","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1056\/NEJMoa1709684","article-title":"Overall survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"377","author":"Wolchok","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.soc.2025.01.003_bib67","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1200\/JCO.2016.67.9258","article-title":"Efficacy and safety of nivolumab alone or in combination with ipilimumab in patients with mucosal melanoma: a pooled analysis","volume":"35","author":"D'Angelo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"15_suppl","key":"10.1016\/j.soc.2025.01.003_bib68","doi-asserted-by":"crossref","first-page":"9013","DOI":"10.1200\/jco.2013.31.15_suppl.9013","article-title":"An update on BREAK-3, a phase III, randomized trial: dabrafenib (DAB) versus dacarbazine (DTIC) in patients with BRAF V600E-positive mutation metastatic melanoma (MM)","volume":"31","author":"Hauschild","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.soc.2025.01.003_bib69","first-page":"2839","article-title":"Kwong BY. Clinical features of drug-induced hypersensitivity syndrome to BRAF inhibitors with and without previous immune checkpoint inhibition: a review","volume":"30","author":"Maloney","year":"2022","journal-title":"Support Care Cancer"},{"issue":"10","key":"10.1016\/j.soc.2025.01.003_bib70","doi-asserted-by":"crossref","first-page":"1789","DOI":"10.1038\/s41591-021-01510-7","article-title":"Neoadjuvant talimogene laherparepvec plus surgery versus surgery alone for resectable stage IIIB-IVM1a melanoma: a randomized, open-label, phase 2 trial","volume":"27","author":"Dummer","year":"2021","journal-title":"Nat Med"},{"issue":"17","key":"10.1016\/j.soc.2025.01.003_bib71","doi-asserted-by":"crossref","first-page":"1714","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology Clinical practice guideline","volume":"36","author":"Brahmer","year":"2018","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.soc.2025.01.003_bib72","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002435","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events","volume":"9","author":"Brahmer","year":"2021","journal-title":"J Immunother Cancer"},{"issue":"4","key":"10.1016\/j.soc.2025.01.003_bib73","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of immunotherapy-related toxicities, version 1.2022, NCCN clinical practice guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"issue":"suppl_4","key":"10.1016\/j.soc.2025.01.003_bib74","doi-asserted-by":"crossref","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","article-title":"Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"28","author":"Haanen","year":"2017","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.01.003_bib75","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1001\/jamaoncol.2023.7333","article-title":"Neoadjuvant dual checkpoint inhibitors vs anti-PD1 therapy in high-risk resectable melanoma: a pooled analysis","volume":"10","author":"Mangla","year":"2024","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.soc.2025.01.003_bib76","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3389\/fonc.2017.00121","article-title":"The feasibility and safety of surgery in patients receiving immune checkpoint inhibitors: a retrospective study","volume":"7","author":"Elias","year":"2017","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.soc.2025.01.003_bib77","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-019-48349-0","article-title":"The effect of preventive use of corticosteroids on postoperative complications after esophagectomy: a retrospective cohort study","volume":"9","author":"Jeong","year":"2019","journal-title":"Sci Rep"},{"issue":"10","key":"10.1016\/j.soc.2025.01.003_bib78","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1007\/s11605-022-05393-y","article-title":"Does chronic use of steroids affect outcomes after liver resection? Analysis of a national database","volume":"26","author":"Aziz","year":"2022","journal-title":"J Gastrointest Surg"},{"issue":"4","key":"10.1016\/j.soc.2025.01.003_bib79","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.01.003_bib80","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1245\/s10434-021-11199-0","article-title":"Adjuvant nivolumab or ipilimumab + nivolumab for melanoma determined by pathological response to a single dose of neoadjuvant nivolumab","volume":"29","author":"Khan","year":"2022","journal-title":"Ann Surg Oncol"},{"issue":"5","key":"10.1016\/j.soc.2025.01.003_bib81","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1158\/2159-8290.CD-22-1180","article-title":"Abatacept\/ruxolitinib and screening for concomitant respiratory muscle failure to mitigate fatality of immune-checkpoint inhibitor myocarditis","volume":"13","author":"Salem","year":"2023","journal-title":"Cancer Discov"},{"issue":"7","key":"10.1016\/j.soc.2025.01.003_bib82","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics13071243","article-title":"Immune checkpoint inhibitors-related myocarditis: a review of reported clinical cases","volume":"13","author":"Zotova","year":"2023","journal-title":"Diagnostics"},{"issue":"3","key":"10.1016\/j.soc.2025.01.003_bib83","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1136\/annrheumdis-2019-216109","article-title":"Immune checkpoint inhibitor-induced inflammatory arthritis persists after immunotherapy cessation","volume":"79","author":"Braaten","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"12","key":"10.1016\/j.soc.2025.01.003_bib84","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.soc.2025.01.003_bib85","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1200\/JCO.2014.57.4756","article-title":"Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis","volume":"33","author":"Teulings","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.soc.2025.01.003_bib86","article-title":"Perioperative management of thyroid dysfunction","volume":"10","author":"Palace","year":"2017","journal-title":"Health Serv Insights"}],"container-title":["Surgical Oncology Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000031?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1055320725000031?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T11:42:18Z","timestamp":1778586138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1055320725000031"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":84,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S1055320725000031"],"URL":"https:\/\/doi.org\/10.1016\/j.soc.2025.01.003","relation":{},"ISSN":["1055-3207"],"issn-type":[{"value":"1055-3207","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Systemic Therapy for Melanoma","name":"articletitle","label":"Article Title"},{"value":"Surgical Oncology Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.soc.2025.01.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}